Molecular TherapyBioengineeringPeer-reviewed journal article
Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing
Irene CarrozzoiD, Giulia MauleiD, Carmelo GentileiD, Alessandro UmbachiD, Matteo CicianiiD, Daniela GuidoneiD, Martina De SantisiD, Gianluca PetrisiD, Luis J. V. GaliettaiD, Daniele ArosioiD, Anna CeresetoiD
Abstract
Cystic Fibrosis (CF) is a life-shortening autosomal recessive disease caused by mutations in the CFTR gene, resulting in functional impairment of the encoded ion channel. F508del mutation, a trinucleotide deletion, is the most frequent cause of CF affecting approximately 80% of patients. Even though current pharmacological treatments alleviate the F508del-CF disease symptoms there is no definitive cure. Here we leveraged revertant mutations (RMs) in cis with F508del to rescue CFTR protein folding and restore its function. We developed CRISPR base editing strategies to efficiently and precisely introduce the desired mutations in the F508del locus. Both editing and CFTR function recovery were verified in CF cellular models including primary epithelial cells derived from CF patients. The efficacy of the CFTR recovery strategy was validated in cultures of pseudostratified epithelia from patients cells showing full recovery of ion transport. Additionally, we observed an additive effect by combining our strategy with small molecules that enhance F508del activity, thus paving the way to combinatorial therapies.
- organism: human
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
- Citations
- 6
- FWCI
- 3.56
- Field percentile
- top 7%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Highly Efficient Repair of the ΔF508 Mutation in Airway Stem Cells of Cystic Fibrosis Patients with Functional Rescue of the Differentiated Epithelia
S. Vaidyanathan, A. A. Salahudeen, … M. H. Porteus·bioRxiv·Feb 26, 2019
- Investigation of Double-Stranded DNA Donors and CRISPR-Cas9 RNP for Universal Correction of Mutations Causing Cystic Fibrosis in Human Airway Cells
Vrishti Sinha, Paul George Ayoub, … Donald B. Kohn·bioRxiv·Sep 21, 2025
- The ΔF508 CFTR defect: molecular mechanism of suppressor mutation V510D and the contribution of transmembrane helix unraveling
K. S. Simon, K. Nagarajan, … G. D. Hurlbut·bioRxiv·Apr 19, 2020
- Targeted replacement of full-length CFTR in human airway stem cells by CRISPR/Cas9 for pan-mutation correction in the endogenous locus
S. Vaidyanathan, R. Baik, … M. Porteus·bioRxiv·Feb 26, 2021
- In vivo correction of cystic fibrosis mediated by PNA nanoparticles
A. S. Piotrowski-Daspit, C. Barone, … M. E. Egan·bioRxiv·Jan 28, 2022
- Gene-Corrected Basal Cells Restore CFTR In Vitro; Transplants Regenerate Epithelium in a Preclinical Sinus Model
Katelin M. Allan, Shaoyan Zhang, … Shafagh A. Waters·bioRxiv·Jul 21, 2025